Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investmen...

Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Cza...

The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be pres...

Eli Lilly (LLY 0.15%) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the...

I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabete...

The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world com...

Healthcare has been one of the toughest sectors for investors over the past year. In fact, over the last 12 months, it has been the worst performing sector in the entire market.

Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India on Wednesday, stepping up compet...

After Eli Lilly & Co. shares fell sharply in the wake of disappointing trial data for its weight-loss pill, several of its executives and board members saw an opportunity to buy.

Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar ...

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by dive...

It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often use...

Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] h...